Sansom review floats curb on novel anticoagulants
A paper outlining the issues and options associated with the new drug class was released last week as part of the Sansom Review of Anticoagulant Therapies in Atrial Fibrillation.
It identified uncertainty about translating trial results to a clinical setting as a key issue.
The paper suggests one option is to restrict the use of novel anticoagulants such as dabigatran (Pradaxa) until more is known about their safety profile or conducting “extensive postmarket surveillance”.
A spokesperson for Boehringer Ingelheim (BI) said efforts to improve warfarin control had been researched for many years, and while it should continue to be researched, many patients urgently needed an alternative.
“BI remains of the view that Pradaxa should be listed on the PBS without further delay,” the company told MO.
Options identified to improve warfarin management included “the use of ‘anticoagulant